摘要
本文对抗CD20单克隆抗体,美罗华(Rituximab)治疗系统性红斑狼疮(SLE)的免疫病理生理,临床疗效及不良反应进行分析总结。美罗华治疗近百例活动性SLE患者的结果显示,80%的SLE活动指数有明显下降,狼疮性肾炎得到临床缓解;90%的患者耐受性好。约10%的患者在输注美罗华期间有轻度过敏反应,个别患者发生严重的机会性感染。初步临床研究提示,美罗华治疗SLE是可行的,其疗效和安全性有待于大样本临床验证。
To identify the clinical efficacy,immunological consequences and adverse effects of anti-CD20 monoclonal antibody in systemic lupus erythematosus. Nearly 100 patients have been reported and a 80% of them achieved marked reduction in global disease activity and clinical remission in lupus nephritis. Anti-CD20 monoclonal antibody is well tolerated in 90% of the patients, though10% of them had hypersensitivity reactions and 4 patients had severe opportunistic infection.
出处
《基础医学与临床》
CSCD
北大核心
2007年第2期206-209,共4页
Basic and Clinical Medicine
